Sorafenib
- PDF / 169,966 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 102 Downloads / 147 Views
1 S
Cardiovascular disorders: 8 case reports In retrospective study of 252 patients treated between May 2006 and March 2020 at the Medical University of Vienna, Austria, 8 patients [ages and sexes not stated] were described, who developed myocardial infarction, ischaemic stroke, deep vein thrombosis, portal vein thrombosis or pulmonary embolism during treatment with sorafenib for hepatocellular carcinoma [route and frequency not stated; not all outcomes and causes of deaths stated]. All the patients were diagnosed with hepatocellular carcinoma. Their medical history included alcoholic liver disease (3 Patients)and viral infection (1 Patient). Five patients had macrovascular invasion. Their concurrent conditions included arterial occlusive disease (2 Patient), diabetes mellitus (4 Patients) and arterial hypertension (2 Patients). All the patients started receiving sorafenib 800mg, 400mg or 200mg. Subsequently, they all developed sorafenib-related adverse events including myocardial infarction and portal vein thrombosis (1 patient), ischemic stroke (1 patient), deep vein thrombosis and portal vein thrombosis (2 patients), deep vein thrombosis (2 Patient), and pulmonary embolism (2 Patients). Framingham risk class was reported as high for 4 patients and low for 2 patients. Time to event onset ranged between 1.4–19.6 months. Owing to adverse events, three patients were treated with low molecular weight heparin with continued sorafenib therapy, one patient underwent percutaneous coronary intervention (PCI), treated with aspirin [ASA]and clopidogrel and sorafenib was discontinued. Sorafenib was interrupted in one patient. Subsequently, two patients died within 14 days. One patient, who had undergone (PCI), died due to myocardial infarction. Pomej K, et al. Vascular complications in patients with hepatocellular carcinoma treated with sorafenib. Cancers 12: 2961, No. 10, Oct 2020. Available from: URL: http:// doi.org/10.3390/cancers12102961 803518494
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
